Prevalence of Comorbidity among the Elderly and Its Impact on Healthcare Expenditure in China
School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China
*Corresponding author:LU Yun,Associate professor;E-mail:luyun78@163.com
[1]ORGANIZATION W H.The World Health Report 2008:primary health care-now more than ever[J].The World Health Report 2008:Primary Health Care-Now More Than Ever,2008,25(7):617.DOI:10.1046/j.1365-3156.1997.d01-129.x.
[2]NUNES B P,FLORES T R,MIELKE G I,et al.Multimorbidity and mortality in older adults: a systematic review and meta-analysis[J].Archives of Gerontology & Geriatrics,2016,67:130-138.DOI:10.1016/j.archger.2016.07.008.
[3]赵明中,胡大一,彭晓霞.老年患者共病及其管理[J].中华老年医学杂志,2015,34(12):1364-1367.DOI:10.3760/cma.j.issn.0254-9026.2015.12.023.
ZHAO M Z,HU D Y,PENG X X.Multimorbidity and its management in older adults[J].Chinese Journal of Geriatrics,2015,34(12):1364-1367.DOI:10.3760/cma.j.issn.0254-9026.2015.12.023.
[4]崔瑶,刘谦,秦明照.老年共病现状及管理策略[J].中国全科医学,2017,20(23):2816-2819.DOI:10.3969/j.issn.1007-9572.2017.06.y54.
CUI Y,LIU Q,QIN M Z.Status and management strategies of multiple chronic conditions in older adults[J].Chinese General Practice,2017,20(23):2816-2819.DOI:10.3969/j.issn.1007-9572.2017.06.y54.
[5]PICCO L,ACHILLA E,ABDIN E,et al.Economic burden of multimorbidity among older adults:impact on healthcare and societal costs[J].BMC Health Services Research,2016,16(1):1-12.DOI:10.1186/s12913-016-1421-7.
[6]闫巍,王杰萍,张洪波,等.老年共病患者在诊疗中面临的问题及应对策略[J].中国全科医学,2018,21(3):261-264.DOI:10.3969/j.issn.1007-9572.2017.00.207.
YAN W,WANG J P,ZHANG H B,et al.Challenges and solutions for elderly patients with multimorbidity during receiving management in China[J].Chinese General Practice,2018,21(3):261-264.DOI:10.3969/j.issn.1007-9572.2017.00.207.
[7]中国健康与养老追踪调查.2015年全国追踪调查[EB/OL].(2017-05-31)[2018-12-10].http://charls.pku.edu.cn/pages/data/111/zh-cn.html.
[8]钱焊森,马爱霞.我国中老年人共病现状及其影响因素分析[J].中国药物评价,2017,34(6):476-480.
QIAN H S,MA A X.Multimorbidity status and its risk factors to multimorbidity in middle-aged people in China[J].Chinese Journal of Drug Evaluation,2017,34(6):476-480.
[9]LEE J T,HAMID F,PATI S,et al.Impact of noncommunicable disease multimorbidity on healthcare utilisation and out-of-pocket expenditures in middle-income countries:cross sectional analysis[J].PLoS One,2015,10(7):103-107.DOI.10.1371/journal.pone.0127199.
[10]WANG S B,D'ARCY C,YU Y Q,et al.Prevalence and patterns of multimorbidity in northeastern China:a cross-sectional study[J].Public Health,2015,129(11):1539-1546.DOI:10.1016/j.puhe.2015.06.013.
[11]WANG H H,WANG J J,WONG S Y,et al.Epidemiology of multimorbidity in China and implications for the healthcare system:cross-sectional survey among 162 464 community household residents in southern China[J].BMC Med,2014,12(1):188.DOI:10.1186/s12916-014-0188-0.
[12]颜俊娴,路云.英国共病管理政策对我国的启示[J].现代商贸工业,2018,39(6):66-68.
YAN J X,LU Y.The enlightenment of British comorbidity management policy to China[J].Modern Business Trade Industry,2018,39(6):66-68.
[13]路云,颜俊娴,华娟.老年人共病管理的研究现状及经验探究[J].卫生经济研究,2017,35(7):58-61.DOI:10.19311/j.cnki.1672-3198.2018.06.028.
LU Y,YAN J X,HUA J.Research status and experience of comorbidity management in the elderly[J].Health Economics Research,2017,35(7):58-61.DOI:10.19311/j.cnki.1672-3198.2018.06.028.